EURASIAN EXPERIMENT JOURNAL OF BIOLOGICAL SCIENCES (EEJBS)
ISSN: 2992-4138 ©EEJBS Publications
Volume 6 Issue 3 2025



# Obesity-Associated Breast Cancer: Inhibition of Aromatase Activity by Natural Products as a Chemopreventive Strategy

**Kibibi Muthoni L.**

**Faculty of Science and Technology Kampala International University Uganda**

## ABSTRACT

The global prevalence of obesity has escalated in recent decades, closely paralleling a rise in hormone-dependent malignancies, notably breast cancer. Obesity contributes to breast cancer risk through multiple mechanisms, including increased aromatase activity, which enhances local estrogen biosynthesis in adipose tissue. Elevated estrogen levels drive the proliferation of estrogen receptor-positive (ER+) breast tumors, particularly in postmenopausal women. Current chemopreventive agents targeting aromatase, such as synthetic aromatase inhibitors (AIs), are associated with side effects and drug resistance. This necessitates the exploration of safer and more effective alternatives. Natural products derived from plants, marine organisms, and dietary sources have emerged as promising modulators of aromatase activity. These bioactive compounds, including flavonoids, polyphenols, lignans, and alkaloids, exhibit anti-aromatase effects through direct enzyme inhibition, modulation of aromatase gene expression, and interference with pro-inflammatory signaling pathways. This review provides an overview of the molecular mechanisms linking obesity to increased aromatase activity and breast cancer progression, and critically evaluates the chemopreventive potential of natural products in this context. Understanding the structure-activity relationships, bioavailability challenges, and synergistic effects with conventional therapies may unlock new frontiers in breast cancer prevention among obese populations.

**Keywords**: Obesity, Breast Cancer, Aromatase Inhibition, Natural Products, Estrogen, Chemoprevention

## INTRODUCTION

Obesity is a well-established and modifiable risk factor for the development and progression of several types of cancer, with postmenopausal breast cancer being among the most prominent[1–3]. The link between obesity and breast cancer is particularly significant for estrogen receptor-positive (ER+) subtypes, which account for a substantial proportion of breast cancer cases in postmenopausal women[4–6]. In the postmenopausal state, when ovarian estrogen production ceases, peripheral tissues, especially adipose tissue become the primary source of estrogen synthesis[7–9]. In obese individuals, the excessive accumulation of adipose tissue leads to increased expression and activity of aromatase (CYP19A1), a key enzyme responsible for the conversion of androgens into estrogens[10]. This heightened aromatase activity results in elevated circulating estrogen levels, creating a hyperestrogenic environment that drives the proliferation of ER+ breast epithelial cells, promotes angiogenesis, and facilitates tumor initiation and progression[11].

Beyond hormonal dysregulation, obesity contributes to breast carcinogenesis through multiple interconnected mechanisms. Chronic low-grade inflammation, insulin resistance, and altered adipokine secretion (e.g., increased leptin and decreased adiponectin) exacerbate the tumor-promoting microenvironment[12–14]. These factors not only enhance aromatase expression but also activate oncogenic signaling pathways such as PI3K/Akt, MAPK, and NF-κB, further accelerating breast cancer progression. Notably, pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), which are elevated in obesity, upregulate aromatase transcription through promoter II and I.4 of the CYP19A1 gene, reinforcing local estrogen production within breast adipose stromal cells[15–17].

Current clinical management of hormone receptor-positive breast cancer often includes the use of synthetic aromatase inhibitors (AIs), such as anastrozole, letrozole, and exemestane. These agents effectively suppress estrogen biosynthesis and have been instrumental in reducing cancer recurrence and improving survival in postmenopausal women[17, 18]. However, the long-term use of AIs is frequently associated with significant adverse effects, including musculoskeletal pain, arthralgia, osteoporosis, and an increased risk of cardiovascular

events. These side effects not only compromise patient adherence but also diminish quality of life, thereby highlighting the need for safer and more tolerable alternatives, particularly for primary prevention in high-risk populations such as obese postmenopausal women[19, 20].

In this context, natural products have garnered significant interest as potential chemopreventive agents due to their multifaceted bioactivity, lower toxicity profiles, and ability to modulate key molecular targets involved in estrogen biosynthesis and breast tumorigenesis[21, 22]. Several plant-derived compounds, including flavonoids (e.g., chrysin, apigenin, and genistein), terpenoids, and polyphenols, have demonstrated aromatase-inhibitory activity in preclinical studies[21]. These natural compounds not only suppress aromatase expression and activity but also exert anti-inflammatory, antioxidant, and antiproliferative effects, thereby offering a dual advantage in the management of obesity-related breast cancer risk. Additionally, certain dietary components and traditional herbal medicines have shown promise in modulating adipokine signaling and reducing systemic inflammation, which may indirectly attenuate aromatase expression and estrogen-driven tumor growth[23].



Moreover, the increasing availability of high-throughput screening technologies and computational modeling tools has facilitated the identification and optimization of bioactive natural products with aromatase-inhibitory potential[24]. Advances in nanotechnology-based drug delivery systems have also enhanced the bioavailability and pharmacokinetic profiles of these compounds, making them more viable candidates for clinical development[25–27].

Targeting aromatase activity in obese postmenopausal women presents a rational and effective strategy for reducing ER+ breast cancer risk. While synthetic AIs remain the cornerstone of hormonal therapy, the exploration of natural products as complementary or alternative agents holds great promise. These compounds not only offer a gentler therapeutic approach with fewer side effects but may also address the broader metabolic and inflammatory disturbances associated with obesity. Continued research into the efficacy, safety, and mechanistic actions of natural aromatase inhibitors is essential for translating these findings into clinical applications and improving outcomes in this high-risk population.

## 2. Obesity, Aromatase, and Breast Cancer: The Pathophysiological Link

Obesity is closely associated with a variety of metabolic disturbances, including insulin resistance, chronic low-grade inflammation, and dysregulation of adipokines such as leptin and adiponectin[12, 28]. These metabolic alterations create a pro-tumorigenic environment, particularly in postmenopausal women, by promoting increased local estrogen biosynthesis. A central mechanism underlying this process is the obesity-induced upregulation of aromatase, the key enzyme responsible for converting androgens to estrogens. In obese individuals, aromatase expression is markedly increased in adipose stromal cells (ASCs), especially in breast tissue. This elevation is primarily driven by inflammatory mediators such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and prostaglandin E2 (PGE2), which are abundantly secreted by infiltrating macrophages and hypertrophic adipocytes[29].

PGE2 enhances aromatase expression by activating the cAMP-PKA-CREB signaling pathway, leading to phosphorylation and nuclear translocation of cAMP response element-binding protein (CREB). CREB, in turn, cooperates with coactivators like peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α) to drive transcription from aromatase promoters I.3 and II, regions particularly active in adipose tissues. Moreover, hyperleptinemia commonly seen in obesity, further stimulates aromatase expression via JAK/STAT signalling [30].

The net effect of these regulatory networks is an increase in CYP19A1 gene transcription, resulting in elevated local estrogen production within the breast microenvironment. This rise in estrogen promotes proliferation and survival of estrogen receptor-positive ($ER^+$) breast cancer cells, enhancing tumor initiation and progression[31]. Hence, the adipose-rich, estrogenic microenvironment in obese individuals presents a unique challenge and an opportunity. Targeting aromatase expression or activity in this context emerges as a critical chemopreventive strategy, especially for postmenopausal women with obesity who are at heightened risk for developing $ER^+$ breast cancer[31].

### Natural Products as Aromatase Inhibitors

Plant-derived natural products have garnered considerable attention for their potential to inhibit aromatase activity, offering a promising, low-toxicity approach to reducing estrogen synthesis in hormone-sensitive cancers[32]. Unlike synthetic aromatase inhibitors, which may be associated with adverse effects such as osteoporosis or cardiovascular risk, many natural compounds offer dual benefits by modulating inflammation, oxidative stress, and hormonal balance. These phytochemicals span diverse structural classes and mechanisms of action, enabling multiple levels of aromatase suppression ranging from direct enzymatic inhibition to indirect regulation via signaling pathways[32].

Among the most studied are flavonoids, polyphenols, lignans, and alkaloids, each demonstrating unique interactions with the aromatase enzyme or its transcriptional machinery. In vitro and in vivo studies suggest these compounds may reduce aromatase expression in adipose stromal cells, inhibit estrogen biosynthesis in

tumor microenvironments, and potentially suppress the growth of $ER^+$ breast cancer cells[33]. Importantly, several of these compounds also target pro-inflammatory mediators and transcription factors implicated in obesity-driven aromatase upregulation, suggesting synergistic value in obese patients[33].

Moreover, structural biology and molecular docking studies have shown that many of these natural products can bind the heme-binding site of aromatase, thereby interfering with its catalytic mechanism. Some even exhibit favorable pharmacokinetic profiles and have been evaluated in preclinical or early-phase clinical trials, either alone or in combination with conventional therapies[33]. Given the increasing prevalence of obesity-associated cancers, especially postmenopausal $ER^+$ breast cancer, these naturally occurring aromatase inhibitors represent a valuable frontier in integrative oncology and chemoprevention.



## 4. Mechanistic Insights into Natural Product Activity

Natural aromatase inhibitors derived from plants and other natural sources exert their anti-estrogenic effects through multiple complementary mechanisms, making them promising candidates for chemoprevention and adjunct therapy in hormone-dependent cancers such as breast cancer[34, 35]. One of the primary modes of action is direct inhibition of aromatase enzyme activity. Certain phytochemicals, such as flavonoids (e.g., chrysin, apigenin, and genistein), exhibit competitive or non-competitive inhibition by binding to the catalytic site of the aromatase enzyme[36, 37]. This interaction prevents the conversion of androgens, such as androstenedione and testosterone, into estrogens like estrone and estradiol. By limiting the enzymatic activity of aromatase, these natural agents help reduce the systemic and local concentrations of estrogen, thereby attenuating estrogen receptor-mediated signaling that drives tumor cell proliferation, particularly in estrogen receptor-positive (ER+) breast cancer[38, 39].

Beyond enzyme inhibition, many natural compounds influence the gene expression of aromatase by targeting transcriptional regulation of the CYP19A1 gene, which encodes the aromatase enzyme. These compounds interfere with promoter regions and modulate upstream signaling pathways that govern CYP19A1 expression. For instance, certain polyphenols and terpenoids have been shown to suppress aromatase mRNA levels by inhibiting transcription factors such as CREB (cAMP response element-binding protein) or by downregulating coactivators like PGC-1α[40]. Additionally, they can influence signaling cascades involving MAPK and PI3K/Akt, which are known to affect CYP19A1 transcription. This transcriptional repression reduces aromatase synthesis at the source, providing a more sustained reduction in estrogen biosynthesis within estrogen-sensitive tissues like the breast and adipose tissue[40]. The ability of these natural products to act at the genetic level offers a long-term strategy for estrogen suppression without the side effects often associated with synthetic aromatase inhibitors.

A third major mechanism involves the anti-inflammatory properties of natural products, which indirectly impact aromatase expression[41, 42]. Chronic inflammation in adipose tissue, especially in obese individuals, leads to increased production of pro-inflammatory mediators such as prostaglandin E2 (PGE2), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), all of which can upregulate aromatase expression through promoter activation. Natural compounds like curcumin, resveratrol, and EGCG (epigallocatechin gallate) exert anti-inflammatory effects by inhibiting the NF-κB signaling pathway and reducing the levels of these pro-inflammatory mediators[42]. Consequently, this results in a downstream reduction of aromatase expression and estrogen biosynthesis. Furthermore, by suppressing inflammation, these agents help modulate the tumor microenvironment, reducing angiogenesis, epithelial-to-mesenchymal transition (EMT), and immune evasion hallmarks of cancer progression[43]. Therefore, the pleiotropic effects of natural aromatase inhibitors not only target estrogen synthesis but also mitigate multiple oncogenic pathways, underscoring their potential in integrative cancer therapy.

## 5. Clinical and Preclinical Evidence

Several natural compounds have progressed from laboratory investigations to clinical or preclinical testing, showing promise in the prevention or adjunct treatment of breast cancer, particularly in estrogen receptor-positive (ER+) subtypes often associated with obesity. One notable example is green tea extract, rich in epigallocatechin gallate (EGCG), which has been evaluated in a Phase II clinical trial involving women at high risk for breast cancer[44, 45]. The study demonstrated a significant reduction in breast tissue estrogen levels, suggesting a favorable modulation of local estrogen biosynthesis, likely through the inhibition of aromatase enzyme activity or regulation of estrogen-responsive genes.

Preclinical studies in animal models further support the potential of natural compounds in chemoprevention. Genistein, a soy isoflavone, and curcumin, a polyphenol derived from turmeric, have both exhibited anti-cancer properties in obese mouse models.[46, 47] These compounds were shown to significantly lower the incidence of mammary tumors and reduce aromatase expression within mammary adipose tissue, highlighting their relevance in obesity-driven breast cancer. Their mechanisms of action include suppression of pro-inflammatory cytokines, inhibition of nuclear factor-kappa B (NF-κB) signaling, and modulation of peroxisome proliferator-activated receptor gamma (PPARγ) activity, all of which are implicated in aromatase gene regulation[48, 49].

Despite these promising findings, several challenges hinder their clinical translation. One major limitation is the poor and variable bioavailability of many phytochemicals when administered orally[50]. Factors such as solubility, absorption, metabolism, and excretion significantly influence systemic exposure. Furthermore, the composition and activity of the gut microbiota play a crucial role in the metabolism and biotransformation of these compounds, ultimately affecting their efficacy[50]. Therefore, strategies such as nano-formulations, bioenhancers, or personalized microbiome-based approaches may be necessary to overcome these barriers and harness the full chemopreventive potential of natural products [51].



## 6. Challenges and Future Directions

Despite promising results from preclinical and small-scale clinical studies, several critical challenges hinder the widespread adoption of natural aromatase inhibitors (AIs) in clinical oncology, particularly for breast cancer chemoprevention and therapy. A primary concern is poor bioavailability, which significantly limits the therapeutic potential of many natural compounds. Phytochemicals such as flavonoids, stilbenes, and lignans often exhibit low water solubility, limited intestinal absorption, rapid first-pass metabolism, and short half-lives. These pharmacokinetic limitations result in subtherapeutic systemic concentrations, making it difficult to achieve sufficient inhibition of aromatase activity in vivo. For example, while curcumin and resveratrol demonstrate potent aromatase inhibitory effects in vitro, their oral bioavailability is notoriously poor, necessitating innovative delivery systems to improve efficacy.

Another major hurdle is the lack of standardization in the formulation and composition of natural product extracts. Natural compounds derived from plant sources are often used as crude or semi-purified mixtures, leading to batch-to-batch variability in active ingredient concentration. This inconsistency complicates dose determination, undermines reproducibility across studies, and poses a challenge for regulatory approval. Additionally, the presence of multiple bioactive constituents in a single extract may lead to synergistic or antagonistic interactions, the mechanisms of which are not fully understood. Without rigorous standardization and quality control measures, translating natural AIs from bench to bedside remains elusive. Advances in analytical chemistry and extraction techniques are essential to produce well-characterized and reproducible formulations suitable for clinical evaluation.

The lack of large-scale, randomized controlled trials (RCTs) is another significant barrier to clinical acceptance. Most of the current evidence supporting the use of natural AIs comes from in vitro models or small-scale, often poorly controlled human trials. While these preliminary studies are valuable for hypothesis generation, they fall short of providing the robust, high-quality data necessary to establish clinical guidelines. Factors such as sample size, heterogeneity of patient populations, and short follow-up periods further limit the interpretability and generalizability of findings. Moreover, the long-term safety profiles of many natural compounds remain unclear, particularly when used chronically or in combination with other therapies. Consequently, there is a pressing need for large, well-designed RCTs that assess not only the efficacy of these agents in reducing estrogen levels and tumor progression but also their pharmacodynamics, toxicity, and interactions with conventional drugs.

To overcome these limitations and fully harness the potential of natural AIs, future research must adopt a multifaceted approach. One promising strategy involves the development of nanoformulations, such as liposomes, solid lipid nanoparticles, and polymer-based carriers, to enhance solubility, stability, and targeted delivery of phytochemicals. These systems can improve bioavailability and ensure controlled release at the tumor site, thereby maximizing therapeutic benefits while minimizing systemic toxicity. In addition, combining natural AIs with existing synthetic aromatase inhibitors or other endocrine therapies may yield synergistic effects and help overcome drug resistance. This combinatorial approach could also reduce the required dose of each agent, potentially lowering side effects. Lastly, conducting comprehensive, multi-center clinical trials with long-term follow-up is crucial for validating the efficacy and safety of natural AIs. Only through such rigorous scientific inquiry can these promising natural compounds be integrated into standard breast cancer management protocols.

## CONCLUSION

Obesity-associated breast cancer presents a growing health challenge, driven in part by increased aromatase-mediated estrogen synthesis in adipose tissue. Natural products offer a promising chemopreventive strategy by targeting aromatase through multiple mechanisms, including direct inhibition, anti-inflammatory action, and modulation of gene expression. With continued research into bioavailability, clinical validation, and combinatorial use with conventional therapies, these compounds hold significant potential in reducing breast cancer risk among obese individuals.

## REFERENCES

1. Aloo, S.O., Barathikannan, K., Oh, D.-H.: Polyphenol-rich fermented hempseed ethanol extracts improve obesity, oxidative stress, and neural health in high-glucose diet-induced *Caenorhabditis elegans*. Food Chemistry: X. 21, 101233 (2024). https://doi.org/10.1016/j.fochx.2024.101233

2. Anand, S., Patel, T.N.: Integrating the metabolic and molecular circuits in diabetes, obesity and cancer: a comprehensive review. Discov Onc. 15, 779 (2024). https://doi.org/10.1007/s12672-024-01662-1
3. Annett, S., Moore, G., Robson, T.: Obesity and Cancer Metastasis: Molecular and Translational Perspectives. Cancers. 12, 3798 (2020). https://doi.org/10.3390/cancers12123798
4. Ejemot-Nwadiaro, R.I., Betiang, P.A., Basajja, M., Uti, D.E.: Obesity and Climate Change: A Two-way Street with Global Health Implications. Obesity Medicine. 56, 100623 (2025). https://doi.org/10.1016/j.obmed.2025.100623
5. Umoru, G.U., Atangwho, I.J., David-Oku, E., Uti, D.E., Agwupuye, E.I., Obeten, U.N., Maitra, S., Subramaniyan, V., Wong, L.S., Aljarba, N.H., Kumarasamy, V.: Tetracarpidium conophorum nuts (African walnuts) up-regulated adiponectin and PPAR-γ expressions with reciprocal suppression of TNF-α gene in obesity. J Cell Mol Med. 28, e70086 (2024). https://doi.org/10.1111/jcmm.70086
6. Atangwho, I.J., David-Oku, E., De Campos, O.C., Udeozor, P.A., Nfona, S.O., Lawal, B.: Modulation of Lipogenesis by Tetracarpidium conophorum Nuts via SREBP-1/ACCA-1/FASN Inhibition in Monosodium-Glutamate-Induced Obesity in Rats. Natural Product Communications. 20, 1934578X251344035 (2025). https://doi.org/10.1177/1934578X251344035
7. Hetemäki, N., Robciuc, A., Vihma, V., Haanpää, M., Hämäläinen, E., Tikkanen, M.J., Mikkola, T.S., Savolainen-Peltonen, H.: Adipose Tissue Sex Steroids in Postmenopausal Women With and Without Menopausal Hormone Therapy. The Journal of Clinical Endocrinology & Metabolism. 110, 511–522 (2025). https://doi.org/10.1210/clinem/dgae458
8. Kuryłowicz, A.: Estrogens in Adipose Tissue Physiology and Obesity-Related Dysfunction. Biomedicines. 11, 690 (2023). https://doi.org/10.3390/biomedicines11030690
9. Qureshi, R., Picon-Ruiz, M., Aurrekoetxea-Rodriguez, I., Nunes de Paiva, V., D'Amico, M., Yoon, H., Radhakrishnan, R., Morata-Tarifa, C., Ince, T., Lippman, M.E., Thaller, S.R., Rodgers, S.E., Kesmodel, S., del Mar Vivanco, M., Slingerland, J.M.: The Major Pre- and Postmenopausal Estrogens Play Opposing Roles in Obesity-Driven Mammary Inflammation and Breast Cancer Development. Cell Metabolism. 31, 1154–1172.e9 (2020). https://doi.org/10.1016/j.cmet.2020.05.008
10. Kuryłowicz, A.: Estrogens in Adipose Tissue Physiology and Obesity-Related Dysfunction. Biomedicines. 11, 690 (2023). https://doi.org/10.3390/biomedicines11030690
11. Mair, K.M., Gaw, R., MacLean, M.R.: Obesity, estrogens and adipose tissue dysfunction – implications for pulmonary arterial hypertension. Pulm Circ. 10, 2045894020952019 (2020). https://doi.org/10.1177/2045894020952023
12. Zhao, C., Hu, W., Xu, Y., Wang, D., Wang, Y., Lv, W., Xiong, M., Yi, Y., Wang, H., Zhang, Q., Wu, Y.: Current Landscape: The Mechanism and Therapeutic Impact of Obesity for Breast Cancer. Front Oncol. 11, 704893 (2021). https://doi.org/10.3389/fonc.2021.704893
13. Uti, D.E., Atangwho, I.J., Omang, W.A., Alum, E.U., Obeten, U.N., Udeozor, P.A., Agada, S.A., Bawa, I., Ogbu, C.O.: Cytokines as key players in obesity low grade inflammation and related complications. Obesity Medicine. 54, 100585 (2025). https://doi.org/10.1016/j.obmed.2025.100585
14. Alum, E.U., Uti, D.E., Ugwu, O.P.-C., Alum, B.N., Edeh, F.O., Ainebyoona, C.: Unveiling the microbial orchestra: exploring the role of microbiota in cancer development and treatment. Discov Onc. 16, 646 (2025). https://doi.org/10.1007/s12672-025-02352-2
15. Sabit, H., Abouelnour, S., Hassen, B.M., Magdy, S., Yasser, A., Wadan, A.-H.S., Abdel-Ghany, S., Radwan, F., Alqosaibi, A.I., Hafiz, H., Awlya, O.F.A., Arneth, B.: Anticancer Potential of Prebiotics: Targeting Estrogen Receptors and PI3K/AKT/mTOR in Breast Cancer. Biomedicines. 13, 990 (2025). https://doi.org/10.3390/biomedicines13040990
16. Esquivel-Velázquez, M., Ostoa-Saloma, P., Palacios-Arreola, M.I., Nava-Castro, K.E., Castro, J.I., Morales-Montor, J.: The Role of Cytokines in Breast Cancer Development and Progression. J Interferon Cytokine Res. 35, 1–16 (2015). https://doi.org/10.1089/jir.2014.0026
17. Devaraji, M., Thanikachalam, P.V.: Phytoconstituents as emerging therapeutics for breast cancer: Mechanistic insights and clinical implications. Cancer Pathogenesis and Therapy. (2025). https://doi.org/10.1016/j.cpt.2025.02.006
18. Tufail, T., Aja, P.M., Offor, C.E., Ibiam, U.A., Ukaidi, C.U.A.: Utilizing Indigenous Flora in East Africa for Breast Cancer Treatment: An Overview. Anticancer Agents Med Chem. 25, 99–113 (2025). https://doi.org/10.2174/0118715206338557240909081833
19. Xiao, M., He, J., Yin, L., Chen, X., Zu, X., Shen, Y.: Tumor-Associated Macrophages: Critical Players in Drug Resistance of Breast Cancer. Front. Immunol. 12, (2021). https://doi.org/10.3389/fimmu.2021.799428
20. Tripathi, S., Sharma, Y., Kumar, D.: Unveiling the link between chronic inflammation and cancer. Metabolism Open. 25, 100347 (2025). https://doi.org/10.1016/j.metop.2025.100347

21. Devaraji, M., Thanikachalam, P.V.: Phytoconstituents as emerging therapeutics for breast cancer: Mechanistic insights and clinical implications. Cancer Pathogenesis and Therapy. (2025). https://doi.org/10.1016/j.cpt.2025.02.006
22. Akwari, A.Ak., Okoroh, P.N., Aniokete, U.C., Abba, J.N., Uti, D.E.: Phytochemicals as modulators of ferroptosis: a novel therapeutic avenue in cancer and neurodegeneration. Mol Biol Rep. 52, 636 (2025). https://doi.org/10.1007/s11033-025-10752-4
23. Chunarkar-Patil, P., Kaleem, M., Mishra, R., Ray, S., Ahmad, A., Verma, D., Bhayye, S., Dubey, R., Singh, H.N., Kumar, S.: Anticancer Drug Discovery Based on Natural Products: From Computational Approaches to Clinical Studies. Biomedicines. 12, 201 (2024). https://doi.org/10.3390/biomedicines12010201
24. Ayon, N.J.: High-Throughput Screening of Natural Product and Synthetic Molecule Libraries for Antibacterial Drug Discovery. Metabolites. 13, 625 (2023). https://doi.org/10.3390/metabo13050625
25. Eyong, E.D., Iwara, I.A., Agwupuye, E.I., Agboola, A.R., Uti, D.E., Obio, W.A., Alum, E.U., Atangwho, I.J.: In vitro and in silico pharmaco-nutritional assessments of some lesser-known Nigerian nuts: Persea americana, Tetracarpidium conophorum, and Terminalia catappa. PLoS One. 20, e0319756 (2025). https://doi.org/10.1371/journal.pone.0319756
26. Atangwho, I.J., Ugwu, O.P.-C., Egbung, G.E., Aja, P.M.: Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics. Journal of Nanobiotechnology. 23, 336 (2025). https://doi.org/10.1186/s12951-025-03412-z
27. Uti, D.E., Atangwho, I.J., Alum, E.U., Ntaobeten, E., Obeten, U.N., Bawa, I., Agada, S.A., Ukam, C.I.-O., Egbung, G.E.: Antioxidants in cancer therapy mitigating lipid peroxidation without compromising treatment through nanotechnology. Discov Nano. 20, 70 (2025). https://doi.org/10.1186/s11671-025-04248-0
28. Uti, D.E., Atangwho, I.J., Eyong, E.U., Umoru, G.U., Egbung, G.E., Rotimi, S.O., Nna, V.U.: African walnuts (Tetracarpidium conophorum) modulate hepatic lipid accumulation in obesity via reciprocal actions on HMG-CoA reductase and paraoxonase. Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets-Immune, Endocrine & Metabolic Disorders). 20, 365–379 (2020)
29. Obasi, D.C., Abba, J.N., Aniokete, U.C., Okoroh, P.N., Akwari, A.Ak.: Evolving Paradigms in Nutrition Therapy for Diabetes: From Carbohydrate Counting to Precision Diets. Obesity Medicine. 100622 (2025). https://doi.org/10.1016/j.obmed.2025.100622
30. Rasha, F., Mims, B.M., Castro-Piedras, I., Barnes, B.J., Grisham, M.B., Rahman, R.L., Pruitt, K.: The Versatility of Sirtuin-1 in Endocrinology and Immunology. Front. Cell Dev. Biol. 8, (2020). https://doi.org/10.3389/fcell.2020.589016
31. Friesenhengst, A., Pribitzer-Winner, T., Miedl, H., Pröstling, K., Schreiber, M.: Elevated Aromatase (CYP19A1) Expression Is Associated with a Poor Survival of Patients with Estrogen Receptor Positive Breast Cancer. Horm Cancer. 9, 128–138 (2018). https://doi.org/10.1007/s12672-017-0317-2
32. Perrone, P., De Rosa, C., D'Angelo, S.: Mediterranean Diet and Agri-Food By-Products: A Possible Sustainable Approach for Breast Cancer Treatment. Antioxidants. 14, 789 (2025). https://doi.org/10.3390/antiox14070789
33. Rispo, F., De Negri Atanasio, G., Demori, I., Costa, G., Marchese, E., Perera-del-Rosario, S., Serrano-Candelas, E., Palomino-Schätzlein, M., Perata, E., Robino, F., Ferrari, P.F., Ferrando, S., Letasiova, S., Markus, J., Zanotti-Russo, M., Grasselli, E.: An extensive review on phenolic compounds and their potential estrogenic properties on skin physiology. Front. Cell Dev. Biol. 11, (2024). https://doi.org/10.3389/fcell.2023.1305835
34. Mitra, S., Dash, R.: Natural Products for the Management and Prevention of Breast Cancer. Evidence-based Complementary and Alternative Medicine : eCAM. 2018, 8324696 (2018). https://doi.org/10.1155/2018/8324696
35. Uti, D.E., Atangwho, I.J., Alum, E.U., Egba, S.I., Ugwu, O.P.-C., Ikechukwu, G.C.: Natural Antidiabetic Agents: Current Evidence and Development Pathways from Medicinal Plants to Clinical use. Natural Product Communications. 20, 1934578X251323393 (2025). https://doi.org/10.1177/1934578X251323393
36. Alam, S., Sarker, Md.M.R., Sultana, T.N., Chowdhury, Md.N.R., Rashid, M.A., Chaity, N.I., Zhao, C., Xiao, J., Hafez, E.E., Khan, S.A., Mohamed, I.N.: Antidiabetic Phytochemicals From Medicinal Plants: Prospective Candidates for New Drug Discovery and Development. Front Endocrinol (Lausanne). 13, 800714 (2022). https://doi.org/10.3389/fendo.2022.800714

37. Hossain, Md.S., Wazed, M.A., Asha, S., Amin, Md.R., Shimul, I.M.: Dietary Phytochemicals in Health and Disease: Mechanisms, Clinical Evidence, and Applications—A Comprehensive Review. Food Sci Nutr. 13, e70101 (2025). https://doi.org/10.1002/fsn3.70101
38. Hossain, Md.S., Wazed, M.A., Asha, S., Amin, Md.R., Shimul, I.M.: Dietary Phytochemicals in Health and Disease: Mechanisms, Clinical Evidence, and Applications—A Comprehensive Review. Food Sci Nutr. 13, e70101 (2025). https://doi.org/10.1002/fsn3.70101
39. Jadimurthy, R., Jagadish, S., Nayak, S.C., Kumar, S., Mohan, C.D., Rangappa, K.S.: Phytochemicals as Invaluable Sources of Potent Antimicrobial Agents to Combat Antibiotic Resistance. Life (Basel). 13, 948 (2023). https://doi.org/10.3390/life13040948
40. Molehin, D., Filleur, S., Pruitt, K.: Regulation of aromatase expression: Potential therapeutic insight into breast cancer treatment. Molecular and Cellular Endocrinology. 531, 111321 (2021). https://doi.org/10.1016/j.mce.2021.111321
41. Abdellatif, K.R.A., Fadaly, W.A.A., Kamel, G.M., Elshaier, Y.A.M.M., El-Magd, M.A.: Design, synthesis, modeling studies and biological evaluation of thiazolidine derivatives containing pyrazole core as potential anti-diabetic PPAR-γ agonists and anti-inflammatory COX-2 selective inhibitors. Bioorganic Chemistry. 82, 86–99 (2019). https://doi.org/10.1016/j.bioorg.2018.09.034
42. Jayarathne, S., Koboziev, I., Park, O.-H., Oldewage-Theron, W., Shen, C.-L., Moustaid-Moussa, N.: Anti-Inflammatory and Anti-Obesity Properties of Food Bioactive Components: Effects on Adipose Tissue. Prev Nutr Food Sci. 22, 251–262 (2017). https://doi.org/10.3746/pnf.2017.22.4.251
43. Es-Sai, B., Wahnou, H., Benayad, S., Rabbaa, S., Laaziouez, Y., El Kebbaj, R., Limami, Y., Duval, R.E.: Gamma-Tocopherol: A Comprehensive Review of Its Antioxidant, Anti-Inflammatory, and Anticancer Properties. Molecules. 30, 653 (2025). https://doi.org/10.3390/molecules30030653
44. Samavat, H., Ursin, G., Emory, T.H., Lee, E., Wang, R., Torkelson, C.J., Dostal, A.M., Swenson, K., Le, C.T., Yang, C.S., Yu, M.C., Yee, D., Wu, A.H., Yuan, J.-M., Kurzer, M.S.: A Randomized Controlled Trial of Green Tea Extract Supplementation and Mammographic Density in Postmenopausal Women at Increased Risk of Breast Cancer. Cancer Prev Res (Phila). 10, 710–718 (2017). https://doi.org/10.1158/1940-6207.CAPR-17-0187
45. Trudel, D., Labbé, D.P., Araya-Farias, M., Doyen, A., Bazinet, L., Duchesne, T., Plante, M., Grégoire, J., Renaud, M.-C., Bachvarov, D., Têtu, B., Bairati, I.: A two-stage, single-arm, phase II study of EGCG-enriched green tea drink as a maintenance therapy in women with advanced stage ovarian cancer. Gynecologic Oncology. 131, 357–361 (2013). https://doi.org/10.1016/j.ygyno.2013.08.019
46. Bertoncini-Silva, C., Vlad, A., Ricciarelli, R., Giacomo Fassini, P., Suen, V.M.M., Zingg, J.-M.: Enhancing the Bioavailability and Bioactivity of Curcumin for Disease Prevention and Treatment. Antioxidants. 13, 331 (2024). https://doi.org/10.3390/antiox13030331
47. Khursheed, R., Singh, S.K., Wadhwa, S., Gulati, M., Jha, N.K., Gupta, G., Devkota, H.P., Prasher, P., Chellappan, D.K., Dua, K.: A sojourn into therapeutic and nutraceutical potential of curcumin and its novel drug delivery system: Current achievements and future perspectives. South African Journal of Botany. 149, 944–962 (2022). https://doi.org/10.1016/j.sajb.2022.04.021
48. Perini, M., Pianezze, S., Ziller, L., Larcher, R., Pace, R.: Stable Isotope Ratio Analysis for the Authentication of Natural Antioxidant Curcuminoids from Curcuma longa (Turmeric). Antioxidants (Basel). 12, 498 (2023). https://doi.org/10.3390/antiox12020498
49. Zheng, B., McClements, D.J.: Formulation of More Efficacious Curcumin Delivery Systems Using Colloid Science: Enhanced Solubility, Stability, and Bioavailability. Molecules. 25, 2791 (2020). https://doi.org/10.3390/molecules25122791
50. Imam, S.S., Alshehri, S., Ghoneim, M.M., Zafar, A., Alsaidan, O.A., Alruwaili, N.K., Gilani, S.J., Rizwanullah, M.: Recent Advancement in Chitosan-Based Nanoparticles for Improved Oral Bioavailability and Bioactivity of Phytochemicals: Challenges and Perspectives. Polymers. 13, 4036 (2021). https://doi.org/10.3390/polym13224036
51. Nwuruku, O.A., Ugwu, O.P.-C., Uti, D.E., Edwin, N.: Harnessing nature: plant-derived nanocarriers for targeted drug delivery in cancer therapy. Phytomedicine Plus. 5, 100828 (2025). https://doi.org/10.1016/j.phyplu.2025.100828


**CITE AS: Kibibi Muthoni L. (2025). Obesity-Associated Breast Cancer: Inhibition of Aromatase Activity by Natural Products as a Chemopreventive Strategy. EURASIAN EXPERIMENT JOURNAL OF BIOLOGICAL SCIENCES 6(3):62-68**